| Expression pattern: |
UP |
| Associated gene: |
CD133, E-cadherin, EpCAM, Ki67 |
| Associated microRNA: |
- |
| Biological function: |
Promotes tumor growth in vivo; enhances liver cancer cell stemness and EMT; associated with poor prognosis. |
| Molecular mechanism: |
Included in a ceRNA network and public-database-based analyses; specific miRNA/mRNA targets for circ-AFAP1 were not reported in the provided text. |
| Biological pathway or process: |
proliferation (promotes); EMT (promotes); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Transfection; In Vivo Animal Model; Western Blot; IHC (Immunohistochemistry) |
| Clinical significance: |
Higher expression in HCC tissues vs paraneoplastic tissues; higher in poor differentiation vs well differentiation; stated as prognostic marker and correlated with poor prognosis. |
| Description: |
circ-AFAP1 (hsa_circ_0069152), derived from liver CSC exosomes, is up-regulated in HCC tumor tissues and associated with stemness features and poor prognosis. Functionally, circ-AFAP1 overexpression increases xenograft tumor volume and modulates stemness/EMT markers (e.g., increased CD133 with decreased E-cadherin and EpCAM), supporting a role in promoting HCC progression via enhancing stemness and EMT. |
| Confidence score: |
0.6616 |